How to Value a Pharmaceutical Distributor in 2026

Pharmaceutical distribution at the national level is dominated by three companies — Cencora (formerly AmerisourceBergen), McKesson, and Cardinal Health — that together control over 90% of U.S. drug distribution by volume. So when I talk about valuing a pharmaceutical distributor, I'm not talking about competing with the Big Three on generic oral solids. I'm talking about the specialty niches where independents still thrive: specialty pharma, oncology, cell and gene therapy, rare disease, compounded sterile products, animal health, and 503B outsourcing.

These businesses can be remarkably valuable. I've seen specialty pharma distributors with $8M in EBITDA trade at multiples general drug wholesalers could never command, because the product mix, cold chain capability, and manufacturer relationships create real strategic scarcity.

The Multiple Range: 4-7x EBITDA

Specialty pharmaceutical distributors trade in a wide 4-7x adjusted EBITDA range, and the spread is dramatic because sub-segment matters enormously.

• 4.0-4.5x EBITDA: Generic-focused short-line wholesalers, low-margin oral solids, no differentiated capability. Buyers are opportunistic.
• 4.5-5.5x EBITDA: Regional specialty distributor with some branded manufacturer relationships, 2-8C cold chain capability, state DEA licensure across a region.
• 5.5-6.5x EBITDA: True specialty platform — oncology, limited distribution drugs (LDD), biologics, rare disease. Multiple manufacturer exclusives or semi-exclusives. VAWD/DSCSA compliant with clean FDA history.
• 6.5-7.5x EBITDA: Cell and gene therapy logistics, ultra-cold chain (−80°C), 503B compounding capability, or nationwide DEA footprint with Schedule II capability. Strategic scarcity drives pricing.

Outliers exist above this range for cell and gene therapy specialists and for businesses with proprietary relationships with high-cost biologic manufacturers, but those are exceptional.

Manufacturer Relationships: The Primary Asset

As with medical device distribution, the manufacturer relationship is the business. But pharma relationships carry additional complexity: many specialty drugs are sold through limited distribution networks(LDDs) where the manufacturer designates three to six authorized distributors nationwide. If you're one of those authorized distributors for a drug doing $500M+ in annual sales, that single relationship can be worth multiple turns of EBITDA.

Buyers will stress-test:

• Contract term and renewal history: How long have you held the LDD spot? Has it been renewed cleanly?
• Exclusivity economics: What's your markup versus the manufacturer's wholesale cost? Specialty pharma margins are thin (2-6% gross) but volumes can be enormous.
• Change of control provisions: Nearly every manufacturer retains the right to review and terminate on sale. Get written pre-consent before closing if possible.
• Pipeline relationships: If your manufacturers have drugs in Phase 3 that will flow through your network, document the projected economics carefully.

Cold Chain Infrastructure as Value Driver

This is where I see sellers underestimate their own value most often. If you've invested in validated 2-8°C refrigerated storage, −20°C or −80°C freezer capability, and validated cold chain shipping with temperature monitoring and excursion management, you have built a barrier to entry that's expensive and time-consuming to replicate.

Cell and gene therapy distribution, which requires cryogenic (−150°C or lower) logistics and white-glove handling, is the most valuable niche of all. Companies with proven CAR-T logistics capabilities routinely trade at 7x+ EBITDA and sometimes get acquired for strategic rather than financial reasons.

For a specialty distributor selling the business, document your cold chain infrastructure meticulously:

• Validated temperature ranges and capacity by zone
• Excursion history and corrective action records
• Qualified shippers and lane validations
• Customer audits passed and pharma quality agreements in place
• Investment in CapEx over the past 3 years

Regulatory: DEA, FDA, and DSCSA Compliance

Pharmaceutical distribution is a heavily regulated business, and regulatory posture directly drives valuation. Every buyer will audit:

DEA registrations. State-by-state DEA licensure for Schedule II-V controlled substances is a real competitive moat. A distributor with Schedule II capability in 40+ states is significantly more valuable than one with only Schedule III-V in 15 states. Suspicious order monitoring (SOM) systems and DEA audit history matter tremendously after the opioid settlements.

State wholesale licensure. You need VAWD (now NABP DDA) accreditation plus individual state licenses. Gaps in your licensure map are deal issues.

DSCSA compliance. The Drug Supply Chain Security Act requires serialization, traceability, and data exchange. Buyers want to see that your systems can handle unit-level tracking and that you're not sitting on legacy infrastructure that will need a forklift upgrade.

FDA inspection history. Form 483s and warning letters will tank a deal faster than anything else. If you have an open FDA issue, resolve it before going to market. Period.

Adjusted EBITDA Considerations

Pharma distributors have unique adjusted EBITDA considerations compared to general distribution:

DIR fees and chargebacks. If you're in a channel with retroactive rebates or direct and indirect remuneration fees, buyers will want to see normalized gross profit after all chargebacks settle. Don't inflate near-term EBITDA with gross profit that will get clawed back.

Inventory revaluation. Specialty pharma inventory can swing in value as manufacturers change WAC pricing. Buyers want to see inventory turns and obsolescence reserves, not just gross margin.

Compliance investment. Legitimate compliance spending — QA headcount, validation consultants, DSCSA systems — should not be added back. Those are structural costs, not one-time items.

Non-recurring FDA/DEA remediation: Genuine one-time legal and consulting related to regulatory issues can be added back if clearly documented.

Who Buys Pharmaceutical Distributors

The Big Three. Cencora, McKesson, and Cardinal Health occasionally acquire specialty distributors to add capabilities their core business lacks. These are typically platform-sized deals ($20M+ EBITDA) and pay premium multiples because the acquirer captures distribution synergies and manufacturer relationships.

Specialty pharmacy platforms. CVS Specialty, Walgreens Specialty, Optum Specialty, and Express Scripts' specialty arm buy distribution-adjacent capabilities to extend their clinical and logistics footprint.

Private equity. Specialty distribution is a busy PE segment. Court Square, New Mountain, Avista, Consonance Capital, and BPOC have all sponsored pharma distribution platforms. Typical platform multiples are 6-7x for scaled specialty businesses.

International strategics. European specialty distributors (Alliance Healthcare, PHOENIX, Walden Group) occasionally buy U.S. platforms as market entry vehicles and have historically paid strategic premiums.

What Kills Value

DEA or FDA enforcement actions. Any active investigation, warning letter, or consent decree is a deal killer. Resolve before marketing.

Manufacturer concentration. If 50%+ of your gross profit comes from one manufacturer's products, buyers will discount aggressively.

Customer concentration in 340B or specialty pharmacy. These segments have their own political and reimbursement risk. Being overly concentrated in either creates deal-specific issues.

Inadequate cold chain validation documentation. If you can't produce clean temperature monitoring records for the past 24 months, buyers will assume compliance risk and price it in.

The Bottom Line

Specialty pharmaceutical distribution rewards operators who have built real infrastructure — cold chain, licensure, quality systems, manufacturer relationships — and punishes those who run the business like a generic wholesaler. If you've invested in the capabilities that actually matter, make sure your sale process tells that story clearly. The difference between a 4.5x and a 6.5x exit on a $6M EBITDA business is $12M of real money. Use our pre-sale preparation framework to build the story 18-24 months before going to market.